-YPGKF-NH2 TFA) Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | C42H50F3N7O9 |
| Molecular Weight | 853.88 |
| Exact Mass | 853.362 |
| CAS # | 1262750-73-1 |
| Related CAS # | tcY-NH2;327177-34-4 |
| PubChem CID | 71311594 |
| Appearance | White to off-white solid powder |
| Hydrogen Bond Donor Count | 8 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 19 |
| Heavy Atom Count | 61 |
| Complexity | 1360 |
| Defined Atom Stereocenter Count | 4 |
| SMILES | C1CN(C([C@@H](NC(/C=C/C2C=CC=CC=2)=O)CC2C=CC(O)=CC=2)=O)[C@H](C(NCC(N[C@H](C(N[C@H](C(N)=O)CC2C=CC=CC=2)=O)CCCCN)=O)=O)C1.O=C(C(F)(F)F)O |
| InChi Key | WQJKBSZTPQERHW-USBDLMLUSA-N |
| InChi Code | InChI=1S/C40H49N7O7.C2HF3O2/c41-22-8-7-14-31(38(52)46-32(37(42)51)24-28-12-5-2-6-13-28)44-36(50)26-43-39(53)34-15-9-23-47(34)40(54)33(25-29-16-19-30(48)20-17-29)45-35(49)21-18-27-10-3-1-4-11-27;3-2(4,5)1(6)7/h1-6,10-13,16-21,31-34,48H,7-9,14-15,22-26,41H2,(H2,42,51)(H,43,53)(H,44,50)(H,45,49)(H,46,52);(H,6,7)/b21-18+;/t31-,32-,33-,34-;/m0./s1 |
| Chemical Name | (2S)-N-[2-[[(2S)-6-amino-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-2-oxoethyl]-1-[(2S)-3-(4-hydroxyphenyl)-2-[[(E)-3-phenylprop-2-enoyl]amino]propanoyl]pyrrolidine-2-carboxamide;2,2,2-trifluoroacetic acid |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | PAR4 |
| ln Vitro | With an IC50 value of 95 μM, tcY-NH2 TFA (0-500 μM) inhibits the aggregation of platelets (obtained from male albino Sprague-Dawley rats) induced by AYPGKF-NH2 (10 μM). With IC50 values of 64 μM for aorta relaxation (RA) and 1 μM for gastric contraction (LM), tcY-NH2 TFA potently activates these processes[1]. tcY-NH2 TFA (Tc-YPGKF-NH2, 400 μM, 5 min) inhibits platelet aggregation and endostatin release that are brought on by thrombin or AY-NH2[2]. In an isolated heart model, tcY-NH2 TFA (5 μM, 15 min) increases recovery of ventricular function by 26% and decreases infarct size (IS) by 51%[5]. |
| ln Vivo | In the Brain Death (BD) rat model, tcY-NH2 TFA (tail vein injection, 0.6 mg/kg for a single dosage) reduces liver injury as seen by improved histomorphology and decreased blood ALT/AST levels[3]. In the draining lymph nodes of burn damage mice model, tcY-NH2 TFA (intraperitoneal injection, 0.6 mg/kg for a single dosage) promotes posttraumatic activation of CD4+ Tregs[4]. In experimental inflammation in mice, tcY-NH2 TFA (intrapleural injection, 40 ng/kg for a single dose) suppresses neutrophil recruitment[6]. |
| Animal Protocol |
Animal/Disease Models: Brain death (BD) rat model[3] Doses: 0.6 mg/kg for a single dose Route of Administration: Tail vein injection for a single dose Experimental Results: decreased blood platelet activation and hepatic platelet accumulation. Attenuated the inflammatory response and apoptosis in the livers. Inhibited the activation of NF-κB and MAPK pathways induced by Brain death (BD). Animal/Disease Models: Burn injury model of C57BL/6 N mice[4] Doses: 0.6 mg/kg for a single dose Route of Administration: intraperitoneal (ip) injection Experimental Results: Increased expression and phosphorylation of PKC-θ in the presence of platelets, without affecting early posttraumatic hemostasis. Animal/Disease Models: BALB/c mice[6] Doses: 40 ng/kg for a single dose Route of Administration: Intrapleural injection Experimental Results: Abolished the number of rolling and adhering neutrophils on the vessel wall. Inhibited CXCL8- and Cg-induced neutrophil migration into the pleural cavity of mice. |
| References |
[1]. Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo. Br J Pharmacol. 2004 Oct;143(4):443-54. [2]. Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist. Br J Pharmacol. 2001 Oct;134(4):701-4. [3]. Blocking protease-activated receptor 4 alleviates liver injury induced by brain death. Biochem Biophys Res Commun. 2022 Mar 5;595:47-53. [4]. Platelets differentially modulate CD4 + Treg activation via GPIIa/IIIb-, fibrinogen-, and PAR4-dependent pathways. Immunol Res. 2022 Apr;70(2):185-196. [5]. Inhibiting protease-activated receptor 4 limits myocardial ischemia/reperfusion injury in rat hearts by unmasking adenosine signaling. J Pharmacol Exp Ther. 2008 Mar;324(3):1045-54. [6]. Blockade of proteinase-activated receptor 4 inhibits neutrophil recruitment in experimental inflammation in mice. Inflamm Res. 2014 Nov;63(11):935-41. |
Solubility Data
| Solubility (In Vitro) | DMSO: 100 mg/mL (117.11 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (2.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1711 mL | 5.8556 mL | 11.7112 mL | |
| 5 mM | 0.2342 mL | 1.1711 mL | 2.3422 mL | |
| 10 mM | 0.1171 mL | 0.5856 mL | 1.1711 mL |